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The aim of this work was to study the vascular effects of dietary supplementation of a nonalcoholic red wine polyphenol extract,
Provinols, in Zucker fatty (ZF) obese rats. ZF or lean rats received diet supplemented or not with Provinols for 8 weeks.
Vasoconstriction in response to phenylephrine (Phe) was then assessed in small mesenteric arteries (SMA) and the aorta with
emphasis on the contribution of cyclooxygenases (COX). Although no difference in vasoconstriction was observed between ZF
and lean rats both in SMA and the aorta, Provinols affected the contribution of COX-derived vasoconstrictor agents. The
nonselective COX inhibitor, indomethacin, reduced vasoconstriction in vessels from both groups; however, lower efficacy was
observed in Provinols-treated rats. This was associated with a reduction in thromboxane-A2 and 8-isoprostane release. The
selective COX-2 inhibitor, NS398, reduced to the same extent vasoconstriction in aortas from ZF and Provinols-treated ZF rats.
However, NS398 reduced response to Phe only in SMA from ZF rats. This was associated with a reduction in 8-isoprostane and
prostaglandin-E release. Paradoxically, Provinols decreased COX-2 expression in the aorta, while it increased its expression in
SMA. We provide here evidence of a subtle and paradoxical regulation of COX pathway by Provinols vessels from obese rats to
maintain vascular tone within a physiological range.
1. Introduction
The incidence of obesity has increased significantly world-
wide in the past decade, reaching epidemic proportions.
Obesity is commonly associated with comorbidities (such
as hypertension, dyslipidaemia, and diabetes) and with
an increased risk of premature death [1]. Obesity, in particu-
lar abdominal obesity, was shown to be a primary contribu-
tor to acquired insulin resistance, as increasing adiposity is
correlated with impaired insulin action [2, 3]. Obesity is also
associated with a broad inflammatory response, particularly,
but not exclusively, in vessels [4, 5].
There are several inflammatory mediators that impact
the vascular function in different animal models of obesity
and metabolic syndrome, such as cyclooxygenase- (COX-)
derived prostanoid derivatives [4–6]. Arachidonic acid is
released by membrane phospholipids through phospholipase
A2 cleavage; it can be metabolized by COX pathway into
prostaglandins and thromboxane A2 (TXA2) [7]. COX exists
in two major isoforms (COX-1 and COX-2) and one variant
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(COX-3) [8]. COX-1 is found in all tissues, while COX-2 is
known as an inducible enzyme that produces, in most cases,
large amounts of prostaglandins. COX-2 is constitutively
expressed in only a few sites, such as parts of the kidney
and central nervous system, but is highly upregulated and
active at the sites of inflammation including vascular
smooth muscle cells and adipose tissue. It is known that
many prostanoid derivatives have specific vasoactive proper-
ties, thereby contributing to the local regulation of vascular
function [9].
Polyphenols constitute one of the most numerous and
ubiquitously distributed group of plant secondary metabo-
lites, present in all plants that are commonly consumed in
the Mediterranean diet, including grains, legumes, fruits,
vegetables, extra virgin olive oil, and red wine [10, 11]. Epide-
miological studies report an inverse association between
dietary polyphenol consumption and mortality from cardio-
vascular diseases [12, 13]. Furthermore, red wine-derived
polyphenols have been reported to improve cardiovascular
function in various animal models of cardiovascular diseases
and metabolic disturbances. For instance, red wine polyphe-
nols were reported to improve endothelial function and
normalise blood pressure in NO-deficient hypertensive rats
[14], in spontaneously hypertensive rats [15] and deoxycorti-
costerone acetate- (DOCA-) salt-induced hypertensive rats
[16]. In addition, red wine polyphenols were found to protect
against cardiac ischemia [17], stroke [18], and improved
cardiac function and endothelial function in obese rats [19].
Dietary polyphenols have also been found to inhibit cellular
enzymes, such as phospholipase A2 and COX, in order to
reduce arachidonic acid and prostaglandin production,
thus exerting an important anti-inflammatory action. Poly-
phenolic compounds extracted from red wine were able to
modulate COX-2 activity and gene expression in different
cell types [20–22].
We have previously reported that dietary red wine poly-
phenol extract, Provinols, improves endothelial function in
the obese Zucker fatty (ZF) rat, a common animal model
of obesity and metabolic syndrome, by reducing oxidative
stress and enhancing nitric oxide (NO) bioavailability
[19]. However, the effects of Provinols on vascular inflam-
mation and vasoreactivity have not yet been studied. The
aim of the present work was therefore to investigate the
vascular effects of a dietary supplementation of Provinols in
ZF rats, with respect to the COX pathway regulation.
2. Materials and Methods
2.1. Animals and Experimental Protocol. All animal studies
were carried out using approved institutional protocols and
conform the Guide for the Care and Use of Laboratory ani-
mals published by US National Institutes of Health (NIH
Publication number 85-23, revised 1996). The study involved
12 Zucker fatty (ZF) rats and 12 of their lean nonobese rats
(Charles River, L’Arbresle, France); all of which received,
for eight weeks, either a control diet or a diet containing a
dose of 20mg/kg/day of Provinols (Société Française de Dis-
tilleries; Vallon Pont d’Arc, France), a nonalcoholic red wine
polyphenol extract. The dose of Provinols given to animals
was described to be able to induce several cardiovascular
protective effects, such as the improvement of endothelial
function [23], the prevention of the increase in blood
pressure in NO-deficient hypertensive rats [14], and the
protection against cardiac ischemia [17], stroke [18], and
improved cardiac function and endothelial function in obese
rats [19]. The eight-week treatment has been reported to
protect against the deleterious effects of hypertension [24]
and chronic stress exposure [25] and obesity [19].
2.2. Vascular Reactivity. Aortic and small mesenteric arteries
(SMA) were obtained from ZF or lean rats having or having
not received Provinols, which were then cleaned from
connective tissue and cut into rings of 1.5–2mm long. Vessel
rings were then mounted on a wire myograph (Danish
MyoTechnology, Aarhus, Denmark) filled with physiological
salt solution (PSS) as described previously [19, 26, 27].
The concentration-response curves were constructed by
cumulative application of phenylephrine (Phe, 1 nmol/L to
10μmol/L; Sigma-Aldrich, St. Quentin, Fallavier, France) to
vessels with functional endothelium in the presence or
absence of a given inhibitor: the NO synthase inhibitor
Nω-nitro-L-arginine methyl ester (L-NAME, 100μmol/L;
Sigma-Aldrich), the selective COX-2 inhibitor N-(2-
cyclohexyloxy-4-nitrophenyl) methanesulfonamide (NS398,
10μmol/L; Sigma-Aldrich), or indomethacin, the nonselec-
tive COX inhibitor (INDO, 100μmol/L). All inhibitors were
used at their maximal active concentrations at which they
inhibit the release of either NO from all isoforms of NO
synthases (L-NAME), metabolites from COX-2 isoforms
(NS398), or metabolites from COX (INDO) in blood vessels,
as reported in our previous studies [26].
2.3. Determination of Prostanoid Production. Vessels with
endothelium were treated with Phe (10μmol/L, 30 minutes,
37°C). The medium was next collected. Then, TXA2, prosta-
glandin E metabolites, prostacyclin, and total 8-isoprostane
were measured by enzyme immunoassays kits (Cayman
Chemicals, Ann Arbor, Michigan). The concentration of
prostanoids was expressed as pg/mL/mg of dry weight (dw)
tissue [28].
2.4. Western Blotting.Aortas and SMA vessels were dissected,
homogenized, and lysed. Proteins (80μg) were separated on
10% SDS-PAGE. Blots were probed with anticyclooxygenase-
(COX-) 1 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-
COX-2 (BD Biosciences, San Jose, CA), and anti-NF-κB p65
(Abcam, Paris, France) antibodies. A monoclonal mouse β-
actin antibody (Sigma-Aldrich) was used at 1/5000 dilution
for visualization of protein gel loading. The membranes were
then washed at least three times in Tris buffer solution con-
taining 0.05% Tween and incubated for 1 hour per wash at
room temperature, with the appropriate horseradish peroxi-
dase- (HRP-) conjugated secondary antibody (Amersham).
The protein antibody complexes were detected by ECL plus
(Amersham) according to the protocol of the manufacturer
as previously done [29, 30].
2.5. Staining and Imaging by Confocal Microscopy. Vessels
with endothelium were frozen and cut into 7μm sections.
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Fixed sections were incubated (2 hours) in blocking buffer
(5% nonfat dry milk in phosphate-buffered saline). After
three washes, tissue sections were incubated overnight with
a polyclonal NF-κB p65 antibody (1 : 100). After three
washes, sections were incubated (1 hour) with murine Alexa
fluor-488-labeled antibody (1 : 100). After washes, vessel sec-
tions were mounted on glass slides and a Solamere confocal
equipment with a DLS-300 laser mounted on a Nikon Eclipse
TE 2000-S inverted microscope was used for the optical
sectioning of the tissue. Digital image recording was per-
formed using the QED in vivo software.
2.6. Carotid Tissue Dual Phase Metabolite Extraction
2.6.1. Extraction Protocol. Frozen sections of carotids
(n = 10, 25± 8mg) were powdered in liquid N2 with a mortar
and pestle and, then, immediately extracted using a dual phase
extraction method [31]. Briefly, frozen tissue fragments were
homogenized for 20 seconds in ice-cold solvents (purex-
analytical-grade) methanol and chloroform in a ratio of
2 : 1 (1.5mL) by using an Ultra-Turrax homogenizer. After
5 minutes in contact with the first solvents at 4°C, 0.5mL
chloroform and 0.5mL distilled water were added and
homogenized. The samples were then centrifuged at 2000
g for 30 minutes. The organic fraction was collected. Vials
were sealed under a flow of Ar and maintained at −20°C.
Prior analysis, lipid extracts were dried off and dissolved
in 400μL of chloroform.
2.6.2. PhospholipidAnalysis.The lipid extract (200μL fromthe
total 400μL) was dried and dissolved in 50μL of chloroform/
methanol (1 : 1, v/v); 20μLwasanalysedbyHPLConaSummit
DIONEX system using an Uptisphere 6OH (5μmol/L)
250× 2mm column. The flow rate was 0.25mL/minute,
and the column temperature was kept at 25°C during all
runs. A light-scattering detector was used for the detection
(Polymer Laboratories PL-ELS2100, Church Stretton,
United Kingdom). The evaporator and nebulisator tempera-
ture was kept, respectively, at 50 and 80°C, and the nitrogen
flow was 1.8mL/minute. A binary solvent system was used
with (A): hexane/isopropanol (82 : 18, v/v) and (B): isopro-
panol/water (85 : 15, v/v) in the presence of triethylamine
(0.014%, v/v) and acetic acid (0.5%, v/v). The gradient pro-
file was started at 5% B for 5 minutes, moved to 35% B in
25 minutes, and then to 85% B in 8 minutes. Finally,
the gradient was returned to the starting conditions in
10 minutes. The column was equilibrated for 10 minutes
before the next run.
2.6.3. Fatty Acid Analysis. Glyceryl triheptadecanoate (2μg)
as internal standard and hexane (1mL) was added to the lipid
extract (80μL from the total 400μL). Transmethylation was
performed for 1 hour in boron trifluoride methanol solution
14% (1mL, Sigma-Aldrich) at 55°C. After the addition of
water (1mL) to the crude, fatty acid methyl esters (FAME)
were extracted with hexane (3mL), dried by evaporation,
and dissolved in ethyl acetate (20μL). FAME (1μL) were
analysed by gas-liquid chromatography [32] on a 5890
Hewlett Packard system using a Famewax RESTEK-fused
silica capillary columns (30m× 0.32mm i.d., 0.25mm film
thickness). Oven temperature was programmed from 110°C
to 220°C at a rate of 2°C per min, and the carrier gas was
hydrogen (0.5 bar). The injector and the flame ionization
detector were at 225°C and 245°C, respectively.
2.6.4. Neutral Lipid Molecular Analysis. Internal standards
were added to the lipid extract (100μL from the total
400μL): 3mg of stigmasterol, 1mg of 1,3-dimyristine, 1mg
of cholesteryl heptadecanoate, and 5mg of glyceryl trihepta-
decanoate. Neutral lipids were separated using a SPE column
(Strata SI-1 Silica 55μm, 70Å, 100mg), washed with 2mL
of chloroform, crudely dissolved in 20μL of chloroform,
applied on the cartridge, and eluted with 2mL of chloro-
form. The organic phases were evaporated until dry and
dissolved in 20μL of ethyl acetate. One μL of the lipid extract
was analysed by gas-liquid chromatography on a FOCUS
Thermo Electron system using a Zebron-1 Phenomenex-
fused silica capillary column (5m× 0.32mm i.d., 0.50mm
film thickness). Oven temperature was programmed from
200°C to 350°C at a rate of 5°C per min, and the carrier gas
was hydrogen (0.5 bar). Profiles of neutral lipid molecular
species were determined according to total acyl carbon num-
ber [32]. The injector and the flame ionization detector were
operating at 315°C and 345°C, respectively.
2.7. Data Analysis. Data are expressed as mean± SEM, and
n represents the number of experiences. Statistical analyses
were performed using a one-way analysis of variance
(ANOVA) and Mann–Whitney U tests or ANOVA for
repeated measures and subsequent Bonferroni’s post hoc
test. P < 0 05 was considered as statistically significant.
3. Results
3.1. Provinols Did Not Affect Contractile Response to Phe in
both Aortas and SMA from ZF Rats. The contractile response
to a vasoconstrictor agonist (Phe) was investigated in both
conductance (aorta) and resistance (SMA) arteries from ZF
and lean rats with or without Provinols treatment. As shown
in Figure 1, there was no significant difference in the contrac-
tile response to Phe between all the groups in both the aorta
and SMA. Due to the absence of differences in overall con-
traction between lean and ZF rats, the rest of the experiments
were carried out on ZF rats only.
3.2. Effect of NO Inhibition on Vascular Reactivity in Aortas
and SMA from ZF Rats. To assess the contribution of NO
levels in vasoconstriction of vessels from ZF and Provinols-
treated ZF rats, NO synthases (NOS) were inhibited using
L-NAME and then contraction in response to Phe was
assessed in both the aorta and SMA. While the nonselective
blockade of NOS did not modify contraction in response to
Phe in SMA from both groups of rats (Figures 2(a), 2(b),
and 2(c)), it potentiated to the same extent the contractile
response to Phe in aortas from both ZF and Provinols-
treated ZF rats (Figures 2(d), 2(e), and 2(f)).
3.3. Provinols Reduced the Involvement of COX-Derived
Vasoconstrictor Metabolites in SMA from Obese Rats. To
figure out the relative contribution of vasoactive prostanoid
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derivatives in the contractile response to Phe in SMA,
COX isoforms were blocked using selective and non-
selective inhibitors. In ZF rats, both COX-2 (NS398)
(Figure 3(a)) and nonselective COX (INDO) (Figure 3(b))
inhibitors reduced to the same extent the contractile
response to Phe in SMA, suggesting the involvement of
COX-2-derived vasoconstrictor metabolites in this con-
tractile response. In Provinols-treated ZF rats, NS398
(Figure 3(c)) failed to affect the contractile response to
Phe; however, indomethacin (Figure 3(d)) reduced con-
traction in SMA, suggesting the implication of non-COX-
2-derived vasoconstrictor metabolites in this contractile
response. Interestingly, when we compared the contractile
response in the presence of inhibitors between the two
groups, we observed that contraction was greater in vessels
from Provinols-treated ZF rats in the presence of COX-2
inhibitor (Figures 3(e) and3(f)), indicating a smaller contribu-
tionofCOX-2-derived vasoconstrictormetabolites in the con-
tractile response to Phe in SMA obtained from ZF rats which
received Provinols compared to ZF rats.
3.4. Provinols Reduced the Involvement of COX-Derived
Vasoconstrictor Metabolites in Aortas from Obese ZF Rats.
The relative contribution of vasoactive prostanoid derivatives
in the contractile response to Phe was assessed in aortas by
inhibiting COX isoforms. Both the nonselective inhibition
of COX and the selective blockade of COX-2 reduced the
contractile response to Phe in aortas from ZF rats; however,
the reduction in contractile response was higher with INDO
(Figures 4(a) and 4(b)), suggesting the participation of both
COX-2- and non-COX-2-derived vasoconstrictor metabo-
lites in the contractile response to Phe in ZF rats. Aortas from
ZF rats which received Provinols exhibited a reduction in the
contractile response to Phe in the presence of NS398 or
INDO; however, the reduction was slightly higher in the
presence of INDO, suggesting the involvement of mainly
COX-2-derived metabolites in the aortas from the polyphe-
nol group (Figures 4(c) and 4(d)).
The comparison of vascular contraction between aortas
from both experimental groups in the presence of inhibi-
tors showed no major differences in the presence of
NS398, although vessels from the polyphenol group had
a trend for a higher contractile response (Figure 4(e));
however, in the presence of INDO, the contraction in ves-
sels from the polyphenol group was significantly greater
(Figure 4(f)), suggesting a reduced involvement of non-
COX-2-derived vasoconstrictor metabolites in aortas from
Provinols-treated ZF rats.
3.5. Provinols Reduced COX-Derived Vasoconstrictor
Metabolite Release in Aortas and SMA from Obese ZF Rats.
The functional studies suggest a reduced participation of
COX-derived vasoconstrictor metabolites in both conduc-
tance and resistance arteries from Provinols-treated ZF rats.
Indeed, in the aorta, the measurement of COX-derived
metabolite production in vessels showed that the Provinols
reduced the release of 8-isoprostane and TXA2, both vaso-
constrictor metabolites, without affecting that of prostacyclin
and prostaglandin E metabolites (Figures 5(a)–5(d)). In
SMA, the Provinols reduced the production of vasoconstric-
tor metabolites 8-isoprostane and prostaglandin E, without
modifying the release of prostacyclin and TXA2 metabolites
(Figures 5(e)–5(h)).
Altogether, these data indicate that the Provinols reduced
the participation of COX-derived vasoconstrictor agents in
the contractile response to Phe in both aortas and SMA.
3.6. Provinols Modulated the Expression of COX Isoforms
and NF-κB in Vessels from Obese ZF Rats. Since Provinols
could modulate the contribution of COX-derived agents in
the contractile response of vessels from obese rats, the
expression of COX-1 and COX-2 was therefore assessed.
Results showed that Provinols did not affect the expression
of COX-1, neither in the aorta nor in SMA (Figures 6(a)
and 6(b)); however, it paradoxically affected the expression
of COX-2 in aortas and SMA. While Provinols reduced
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Figure 1: Provinols did not affect contractile response to Phe in aortas and SMA from obese ZF rats. Shown are concentration-response
curves to phenylephrine (Phe) cumulative concentrations (M) of small mesenteric arteries (SMA, (a)) and rat aortic rings (b) from lean
and ZF rats treated or not with Provinols. Values are expressed as mean± SEM of millinewtons (mN) per mm of vessel length. N = 6 in
each group.
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COX-2 expression in the aorta, it enhanced its expression
in SMA, (Figures 6(c) and 6(d)).
The transcription factor NF-κB controls the transcription
of proinflammatory enzymes such as COX-2; hence, its
expression was assessed. The expression of NF-κB was signif-
icantly reduced by Provinols within the aorta (Figures 6(e)
and 6(f)); however, its expression did not change in SMA
(Figure 6(g)).
3.7. Provinols Altered Phospholipid Profile in Carotids from
Obese ZF Rats. An alteration in the activity of phospholi-
pase A2, primarily responsible of prostanoid derivatives
generation, may lead to an alteration of the lipid com-
position in vessels from ZF obese rats. Hence, the effects
of Provinols on the distribution of membrane neutral lipids
and fatty acids were analysed in carotid artery from ZF rats.
As shown in Table 1, the neutral lipid composition
and fatty acid composition of total lipids from carotid
tissues remained similar in Provinols-treated and control
groups. Neither concentrations nor percent distribution
of neutral lipid molecular species of triacylglycerides
(TAG), diacylglycerides D (AG), nor cholesteryl esters
were modified by Provinols (Table 1). Moreover, Provinols
did not modify neither the concentration nor the distribu-
tion of fatty acid molecular species of saturated fatty acids
(SAFA), monounsaturated fatty acids (MUFA), and poly-
unsaturated fatty acids (PUFA) (Table 2). However, even
though phospholipid contents were similar in the two
groups, Provinols led to an alteration of the phospholipid’s
profile. As shown in Table 3, Provinols significantly increased
the contribution of phosphatidylethanolamine (PE) to total
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Figure 2: Effect of NO inhibition on vasoreactivity in aortas and SMA from obese ZF rats. Shown are concentration-response curves to
phenylephrine (Phe) cumulative concentrations (M) in the presence of NO-synthase nonselective inhibitor (L-NAME) of small mesenteric
arteries (SMA) (a–c) and rat aortic rings (d–f) from ZF rats treated or not with Provinols. Values are expressed as mean± SEM of
millinewtons (mN) per mm of vessel length. ∗∗∗P < 0 001 versus ZF rats.
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phospholipids (41.6 ± 6.4 nmol/mg and 50± 2.7 nmol/mg
from nontreated and Provinols-treated ZF rats, respectively).
4. Discussion
Our findings reported in this study indicated that red wine
polyphenols modulated the relative contribution of COX-
derived metabolites in vasoreactivity in both conductance
and resistance arteries from ZF rats, although without
affecting the global contractile response of vessels. Indeed,
Provinols could reduce the release of COX-derived vasocon-
strictor agents from both types of arteries by affecting the
expression and/or activity of COX enzymes as well as NF-
κB transcription factor. In addition, Provinols treatment
altered the phospholipid molecular species distribution in
carotid arteries from ZF rats. These data underscore the
beneficial role of red wine polyphenols in modulating
the contribution of inflammatory agents in the control of
vascular tone in obese rats.
In a previous study, we showed that ZF rats had an
impaired endothelium-dependent relaxation to acetylcholine
compared to their lean controls [19]; however, the present
study demonstrated that there was no difference in the
contractile response to Phe between control and obese rats.
In a study by Mingorance et al. [5], authors found that aortas
and SMA from ZF rats had a lower response to Phe than lean
animals, whereas ZF rats showed a diminished response to
acetylcholine only in the aorta. The discrepancy between
our findings and those from Mingorance et al. may be
due to the age of animals used, 15 weeks in our study
and 31 weeks of age in the other one. In addition, an
exaggerated adrenergically mediated vascular reactivity
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Figure 3: Provinols reduced the involvement of COX-derived vasoconstrictor metabolites in SMA from obese ZF rats. Concentration-
response curves to phenylephrine (Phe) cumulative concentrations (M) in the presence of COX-2 inhibitor (NS398) or the
nonselective COX inhibitor (indomethacin, INDO) of small mesenteric arteries (SMA) from ZF rats which received or not Provinols.
N = 6 in each group. Values are expressed as mean± SEM of millinewtons (mN) per mm of vessel length. ∗P < 0 05; ∗∗P < 0 01;
∗∗∗P < 0 001 versus ZF rats.
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has been also documented in aortic and SMA rings from
obese rats [33, 34].
Although no difference was observed in the contractile
response to Phe, we observed that Provinols treatment signif-
icantly modulated the relative contribution of COX-derived
metabolites in vasoreactivity in both the aorta and SMA. Of
note, SMA from ZF rats had more contribution from COX-
2-derived vasoconstrictor metabolites in the contractile
response to Phe compared to vessels from ZF rats fed a diet
containing Provinols. Aortas from ZF rats had, however,
more contribution from non-COX-2-derived vasoconstrictor
agents in the contractile response to Phe in comparison to
aortas from the polyphenol group. Consistent with these
findings, the evaluation of prostanoid derivative release
revealed that vasoconstrictor COX-derived agents were
reduced in the Provinols group (8-isoprostane/TXA2 in the
aorta and 8-isoprostane/prostanglandin E in SMA). Interest-
ingly, previous studies showed an increased participation of
COX-derived vasoconstrictor agents (i.e., TXA2) in vessels
from ZF rats compared to lean controls [4, 5]. Both the aorta
and SMA from the Provinols group had reduced levels
of 8-isoprostane production, indicating a reduction of oxida-
tive stress. Indeed, in contrast to classic prostaglandins,
isoprostanes are formed by free radical-catalysed lipid perox-
idation of arachidonic acid and cell membrane phospholipids
and constitute thus a good marker for oxidative stress level.
These observations are in line with our previous results
which indicated that Provinols reduced superoxide anion
release in aortas and SMA from ZF rats [19].
Findings from our study support previous reports
demonstrating that polyphenols can regulate COX-2 expres-
sion and secretion [35, 36]. In this study, we observed that
Provinols did not affect the expression of the constitutive
COX-1 isoform in both the aorta and SMA; paradoxically,
however, Provinols reduced COX-2 expression in the aorta
and enhanced its protein expression in SMA. These results
are not in apparent line with our functional findings or those
of biochemical analysis of COX-derived metabolites release.
The reduction in COX-2 expression in aortas may explain
the reduction of the release of COX-derived metabolites. This
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is further corroborated by the reduction of NF-κB transcrip-
tion factor expression in aortas from the polyphenol group.
The activation of NF-κB is upstream of the synthesis of
acute phase inflammatory mediators. Among the genes
known to be positively regulated by NF-κB is COX-2 [37].
In the present work, we found that Provinols reduced NF-
κB in the aorta, but not in SMA, accounting potentially
for reducing COX-2 expression. Previously, it has been
shown that tea polyphenols inactivated phosphorylated
forms of nuclear NF-κB and reduced COX-2 expression in
rat mammary tumours [38]. Furthermore, procyanidin
extracts, a mixture of polyphenols, inhibited NF-κB
(p65) translocation in lipopolysaccharide-stimulated mac-
rophages [39].
In SMA from rats treated with polyphenols, we observed
an increase in COX-2 expression even though functional data
and biochemical analysis indicated that these vessels have
less contribution of COX-2-derived metabolites towards the
contractile response to Phe. This paradoxical effect could be
explained by a subtle effect of Provinols on the activity of
COX enzymes and/or phospholipase A2 activity, which
would contribute to the reduced release of COX-derived
Table 1: Comparison between neutral lipid molecular species from
carotids in control and Provinols-treated rats.
Neutral lipids ZF ZF+ Provinols
Percent distribution of TAG
TAG C49 4.7± 0.3 3.8± 0.6
TAG C51 13.5± 0.8 12.1± 1.3
TAG C53 32± 0.9 31.4± 1
TAG C55 34.6± 1 35.77± 1.2
TAG C57 13.3± 0.7 14.6± 1.2
TAG C59 1.8± 0.4 2.4± 0.6
Total TAG (nmol/mg) 4.68± 1.72 4.36± 1.35
Percent distribution of DAG
DAG 14–16 16.9± 11.6 12± 2.5
DAG 16-16 19.6± 6.7 14.4± 4.4
DAG 16–18 34± 9.2 43± 5.3
DAG 18-18 17± 14.7 19± 11.2
DAG18–20 12± 2.5 14± 0.3
DAG18–22 Nd Nd
Total DAG (nmol/mg) 0.10± 0.03 0.08± 0.03
Percent distribution of cholesteryl esters
C14 cholesteryl ester Nd Nd
C16 cholesteryl ester 15.1± 1.7 17.3± 3.8
C18 cholesteryl ester 17.9± 6 17.6± 5.1
C20:4 cholesteryl ester 67± 6.1 65.1± 8.3
C22 cholesteryl ester Nd Nd
Total cholesteryl esters (nmol/mg) 1.8± 0.6 0.13± 0.03
Cholesterol (nmol/mg) 0.12± 0.04 1.6± 0.3
Data are means ± SEM. Nd: not detected. Concentrations are expressed as
nanomoles per mg of tissue wet weight (nmol/mg). Triacylglycerides
(TAG) and diacylglycerides (DAG) families were defined according to
their total number of carbon atoms (as described in Materials and Methods).
Table 2: Comparison between fatty acid (FA) molecular species
from carotids in control and Provinols-treated rats.
FA ZF ZF +Provinols
Total FA (nmol/mg) 14.59± 4.58 19.74± 6.43
Percent distribution of FA
SAFA 41.5± 2.4 40.9± 1.3
MUFA 38.1± 4.9 39.7± 1.4
PUFA 20.4± 2.6 19.4± 2.1
Percent distribution of SAFA
14 : 0 3.3± 0.7 3.4± 1.3
16 : 0 72.6± 5.9 72.5± 2.7
18 : 0 22± 4.4 22.9± 3.6
20 : 0 1.1± 0.5 0.6± 0.2
24 : 0 1.1± 0.8 0.6± 0.2
Percent distribution of MUFA
16 : 1 n-7 17.8± 0.8 17± 2.4
18 : 1 n-9 78.5± 4.3 82± 2
20 : 1 n-9 0.4± 0.1 0.4± 0.2
22 : 1 n-9 Nd Nd
24 : 1 n-9 3.3± 4.5 0.6± 0.3
Percent distribution of PUFA
18 : 2 n-6 53.1± 11.7 57.9± 9.3
18 : 3 n-6 Nd Nd
18 : 3 n-6 2.1± 0.8 2.3± 0.6
20 : 2 n-6 1.3± 0.3 1.4± 0.4
20 : 3 n-6 Nd Nd
20 : 3 n-6 1.7± 0.4 1.6± 0.4
20 : 4 n-6 38.5± 12 33.2± 9.2
20 : 5 n-3 Nd Nd
22 : 5 n-3 Nd Nd
22 : 2 n-6 Nd Nd
22 : 6 n-3 3.3± 1 3.4± 1
Data are means ± SEM. Total fatty acids (FA) are expressed as nanomoles
per mg of tissue wet weight. SAFA: saturated fatty acids; MUFA:
monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; Nd:
not detected.
Table 3: Comparison between phospholipids (PL) from carotids in
control and Provinols-treated rats.
Percent distribution of PL ZF ZF +Provinols
PE 41.6± 6.4 50± 2.7∗
PC 38± 5.7 33.9± 1.9
SM 13± 4.4 9.4± 1
PS 4.8± 1.2 4.3± 0.6
PI 2.6± 1.6 2.5± 0.4
PG Nd Nd
Total PL (nmol/mg) 3.8± 1.3 3.6± 0.9
Data are means ± SEM. Total phospholipids (PL) are expressed as
nanomoles per mg of tissue wet weight. ∗Difference between groups at
P < 0 05 (n = 5). PE: phosphatidylethanolamine; PC: phosphatidylcholine;
SM: sphigomyeline; PS: phosphatidylserine; PI: phosphatidylinositol, PG:
phosphatidylglycerol; Nd: not detected.
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metabolites. The increase in COX-2 protein expression may
therefore be a compensatory mechanism to the decrease
in the enzyme’s activity. Although the reduction in
COX-derived metabolites caused by Provinols may suggest
a reduction in COX activity, further studies are warranted
to ascertain the effects of Provinols on COX enzymes’
activity. Consistent with our findings, a previous study
from Kane et al. [40] showed that red wine polyphenols
reduced angiotensin II-induced COX-2 overexpression in
rat vessels. Previous publications have also reported an
inhibitory effect of red wine extract and tea polyphenols
on COX-2 activity [20, 38]. However, a recent study eval-
uated the effect of several food polyphenols, including
resveratrol, a component of red wine polyphenols, on
the activity of COX-2 and reported that although these
compounds could elicit the inhibition of COX–2, their
potency was 100- to 1000-fold lower compared to known
pharmacological inhibitors of COX-2 such as celecoxib
and indomethacin [41].
Finally, we have shown that one focal effect of Provinols
treatment was an alteration of phospholipid molecular
species in carotid arteries from ZF rats. The increase in the
PE contribution to total phospholipids suggested that Provi-
nols treatment had a specific effect on phospholipid turnover
because neutral lipids and fatty acid molecular species
remain unchanged. Indeed, a reduction in PE degradation
has been previously observed in platelets and liver micro-
somes due to inhibition of the secretory phospholipase A2
[42]. This result is suggestive of a reduction in the activity
of phospholipase A2 in vessels from Provinols-treated rats
especially when taken together with the reduction in the
secretion of bioactive prostanoids.
In conclusion, we showed in this study that the global
response to vasoconstrictor agonists was not altered in ZF
compared to lean rats; however, red wine polyphenols could
modulate COX expression and/or activity via a mechanism
involving NF-κB pathway. The present study provided evi-
dence of a subtle regulation of vasocontractility both in con-
ductance and resistance arteries by Provinols to maintain
vascular tone within a physiological range. Such effect is
linked to a paradoxical effect of Provinols on COX path-
way. These data highlight further the beneficial role of
red wine polyphenols in correcting cardiovascular distur-
bances associated with obesity and metabolic syndrome.
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